MAP17 Enhances Chemoresistance and Tumorigenicity of Glioblastoma‐Initiating Cells via the Canonical NF‐кB Pathway
Cancer Science · 2026
DOI: 10.1111/cas.70385 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Shenshen Dou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Stem Cell Biology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: Glioblastoma, Drug Resistance, Neoplasm, Brain Neoplasms, NF-kappa B. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AMED Practical Research for Innovative Cancer Control, JSPS KAKENHI Grant-in-Aid for Scientific Research, The Joint Research Program of the Institute for Genetic Medicine Hokkaido University.
Abstract (Originalsprache)
Glioblastoma (GBM) is the most common malignant brain tumor in adults. Despite multimodal treatments, including surgery, radiation therapy, and temozolomide (TMZ) chemotherapy, the median survival remains poor at approximately 15 months. One reason for the therapeutic resistance is the existence of GBM‐initiating cells (GICs) within the tumor. Therefore, understanding the molecular insights of how GICs contribute to the therapy recurrence is crucial for developing new therapeutic strategies. Comparing expression profiles of TMZ‐resistant GICs (GICRs) with those of GICs, we identified membrane‐associated protein 17 (MAP17) as a new factor that is exclusively expressed in GICRs. We show that overexpression of MAP17 in GICs significantly increased their proliferation, TMZ resistance, and tumorigenicity, whereas its knockdown impaired these properties, indicating that MAP17 plays a critical role in both TMZ resistance and tumorigenicity of GICs. We also show that MAP17 increased the expression of anti‐apoptotic protein BCL2 through the activation of RELA‐dependent NF‐κB pathway in GICs. Furthermore, we demonstrate that overexpression of BCL2 increased TMZ resistance in GICs and their tumorigenicity, while its knockdown deprived these malignant characters in GICRs. Taken together, these findings identify a novel signaling pathway, MAP17‐NF‐κB‐BCL2, that controls TMZ resistance and tumorigenicity of GICs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Stem Cell Biology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
ORCID-Profile: You Lee Son
Förderung
- AMED Practical Research for Innovative Cancer Control
- JSPS KAKENHI Grant-in-Aid for Scientific Research
- The Joint Research Program of the Institute for Genetic Medicine Hokkaido University
Zitieren
APA
Dou, S., Son, Y. L., & Kondo, T. (2026). MAP17 Enhances Chemoresistance and Tumorigenicity of Glioblastoma‐Initiating Cells via the Canonical NF‐кB Pathway. Cancer Science. https://doi.org/10.1111/cas.70385
Vancouver
Dou S, Son YL, Kondo T. MAP17 Enhances Chemoresistance and Tumorigenicity of Glioblastoma‐Initiating Cells via the Canonical NF‐кB Pathway. Cancer Science. 2026. doi:10.1111/cas.70385
BibTeX
@article{Dou2026,
author = {Dou, Shenshen and Son, You Lee and Kondo, Toru},
title = {MAP17 Enhances Chemoresistance and Tumorigenicity of Glioblastoma‐Initiating Cells via the Canonical NF‐кB Pathway},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70385}
}
EUVIMED